

Aditya Bagrodia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2021759/publications.pdf>

Version: 2024-02-01

205
papers

5,815
citations

94433

37
h-index

95266

68
g-index

211
all docs

211
docs citations

211
times ranked

6056
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	0
2	Evaluation of a risk-adapted strategy in the primary surgical management of clinical stage IIA testicular cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 414-414.	1.6	0
3	Molecular analysis of primary testicular germ cell tumor and matched metastatic teratomas.. <i>Journal of Clinical Oncology</i> , 2022, 40, 425-425.	1.6	0
4	Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 779182.	2.8	0
5	Evaluating the discriminatory capacity of miR-371A-3P in the context of pure seminomatous testicular cancer metastases.. <i>Journal of Clinical Oncology</i> , 2022, 40, 424-424.	1.6	0
6	Optimization of serum miR-371a-3p for the detection of chemotherapy-naïve minimal residual germ cell tumor.. <i>Journal of Clinical Oncology</i> , 2022, 40, 423-423.	1.6	0
7	Role of preoperative albumin in predicting risk of postoperative complications in patients undergoing post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. <i>Journal of Clinical Oncology</i> , 2022, 40, 416-416.	1.6	0
8	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. <i>World Journal of Urology</i> , 2022, 40, 1505-1512.	2.2	12
9	Predictive factors of diagnostic delay and effect on treatment patterns in testicular germ cell tumor patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 201.e1-201.e7.	1.6	3
10	Circulating MicroRNAs for Detection of Germ Cell Tumours: A Narrative Review. <i>European Urology Focus</i> , 2022, 8, 660-662.	3.1	10
11	Clinicopathologic predictors of outcomes in children with stage I testicular germ cell tumors: A pooled post hoc analysis of trials from the Children's Oncology Group. <i>Journal of Pediatric Urology</i> , 2022, 18, 505-511.	1.1	2
12	Safety and Feasibility of Telehealth Only Preoperative Evaluation Before Minimally Invasive Robotic Urologic Surgery. <i>Journal of Endourology</i> , 2022, 36, 1070-1076.	2.1	4
13	Decreased Muscle Mass Prior to and Following Chemotherapy Predicts Morbidity in Testicular Cancer Patients Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e460-e464.	1.9	0
14	Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. <i>World Journal of Urology</i> , 2021, 39, 1977-1984.	2.2	9
15	Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample. <i>BJU International</i> , 2021, 128, 168-177.	2.5	15
16	Magnetic Resonance Imaging Radiomics Analyses for Prediction of High-Grade Histology and Necrosis in Clear Cell Renal Cell Carcinoma: Preliminary Experience. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 12-21.e1.	1.9	22
17	Robotic Nephroureterectomy <i>vs</i> Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically. <i>Journal of Endourology</i> , 2021, 35, 312-318.	2.1	18
18	Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 127, 108-113.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. <i>Cancer</i> , 2021, 127, 850-864.	4.1	24
20	Dynamic differences between DNA damage repair responses in primary tumors and cell lines. <i>Translational Oncology</i> , 2021, 14, 100898.	3.7	6
21	Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. <i>Journal of Urology</i> , 2021, 205, 137-144.	0.4	28
22	Validation of testicular germ cell tumor (GCT) staging in nationwide cancer registries.. <i>Journal of Clinical Oncology</i> , 2021, 39, 383-383.	1.6	0
23	Real-world application of pre-orchietomy miR-371a-3p test in testicular germ cell tumor (GCT) management.. <i>Journal of Clinical Oncology</i> , 2021, 39, 387-387.	1.6	2
24	Clinical utility of the AJCC 8th edition pT1 subclassification and impact on practice patterns in stage I seminoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 136.e19-136.e25.	1.6	3
25	Sarcopenia prior to and following chemotherapy to predict morbidity in patients undergoing post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND).. <i>Journal of Clinical Oncology</i> , 2021, 39, 381-381.	1.6	0
26	Pre-orchietomy serum tumor markers as a predictor of recurrence in stage I germ cell tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 389-389.	1.6	2
27	Clinical utility of the AJCC eighth edition pT1 subclassification and impact on practice patterns in stage I seminoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 377-377.	1.6	2
28	Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 311-311.	1.6	5
29	Reply to So, now what?: Reflections on socioeconomic factors, testicular cancer, and health care accessibility. <i>Cancer</i> , 2021, 127, 1347-1348.	4.1	0
30	Re: Lucia Nappi, Marisa Thi, Nabil Adra, et al. Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. <i>Eur Urol</i> 2021;79:16-19. <i>European Urology</i> , 2021, 79, e96-e97.	1.9	2
31	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	2.1	51
32	Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRI-Transrectal US Fusion Prostate Biopsies. <i>Radiology Imaging Cancer</i> , 2021, 3, e200123.	1.6	12
33	Encouraging Outcomes Allow Patient-Guided Treatment Strategies for Stage I Pure Testicular Teratoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3465-3467.	1.5	0
34	The Road Ahead for Circulating microRNAs in Diagnosis and Management of Testicular Germ Cell Tumors. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 269-271.	3.8	6
35	Safety, Efficacy, and Impact on Quality of Life of Palliative Robotic Cystectomy for Advanced Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e129-e134.	1.9	1
36	Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>European Urology Open Science</i> , 2021, 26, 83-87.	0.4	26

#	ARTICLE	IF	CITATIONS
37	Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e1-790.e7.	1.6	10
38	How can we mitigate treatment-associated morbidity in patients with germ cell tumors?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 805-807.	2.4	0
39	Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombusâ€”Safety Lead-in Results of a Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1135-1142.	0.8	36
40	Disparities in Pre-Orchiectomy Sperm Cryopreservation Among Testicular Cancer Patients at a Public Safety Net Hospital and a Private Tertiary Care Center. <i>Urology</i> , 2021, , .	1.0	1
41	Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 788.e15-788.e21.	1.6	2
42	Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. <i>Clinical Cancer Research</i> , 2021, 27, 4794-4806.	7.0	17
43	Progress and challenges in testicular cancer microRNAs. <i>Asian Journal of Urology</i> , 2021, 8, 341-342.	1.2	0
44	Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. <i>Advances in Radiation Oncology</i> , 2021, 6, 100692.	1.2	18
45	A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 469-479.	1.9	19
46	The early impact of medicaid expansion on urologic malignancies in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 103.e1-103.e1.	1.6	1
47	Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 724682.	2.8	3
48	Validation of testicular germ cell tumor staging in nationwide cancer registries. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 838.e1-838.e6.	1.6	2
49	Germ Cell Tumor Cell Culture Techniques. <i>Methods in Molecular Biology</i> , 2021, 2195, 65-76.	0.9	0
50	Performance characteristics of 18F-fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection. <i>Canadian Urological Association Journal</i> , 2021, 16, E167-E172.	0.6	1
51	Re: Anthony Emmanuel, Abi Kanthabalan, Cameron Alexander, et al. Expedited Radical Orchiectomy for Testicular Cancer: Compromising Fertility Outcomes Without Oncological Benefit? <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2021.08.025 . <i>European Urology</i> , 2021, 81, e50-e50.	1.9	0
52	Considerations When Treating Patients with Good-risk Germ Cell Tumors. <i>European Urology Focus</i> , 2020, 6, 1195-1198.	3.1	0
53	Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. <i>European Urology Oncology</i> , 2020, 3, 198-206.	5.4	9
54	Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. <i>European Urology</i> , 2020, 77, 290-292.	1.9	48

#	ARTICLE	IF	CITATIONS
55	Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 736.e11-736.e18.	1.6	8
56	Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. BJU International, 2020, 128, 57-64.	2.5	14
57	Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. Cancer, 2020, 126, 4362-4370.	4.1	14
58	Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma. Urology, 2020, 145, 159-165.	1.0	7
59	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO Precision Oncology, 2020, 4, 1307-1320.	3.0	9
60	Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 933.e7-933.e12.	1.6	10
61	Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management. American Journal of Roentgenology, 2020, 215, 267-276.	2.2	9
62	Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 737.e11-737.e16.	1.6	10
63	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 604.e9-604.e17.	1.6	77
64	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications, 2020, 11, 1975.	12.8	37
65	Overcoming sociodemographic factors in the care of testicular cancer patients at a safety net hospital.. Journal of Clinical Oncology, 2020, 38, 398-398.	1.6	0
66	Performance characteristics of 18F-Fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection.. Journal of Clinical Oncology, 2020, 38, 390-390.	1.6	1
67	Genomic determinants of nested variant urothelial carcinoma.. Journal of Clinical Oncology, 2020, 38, 538-538.	1.6	0
68	Effect of increasing Medicaid coverage in Medicaid expansion states on stage at presentation for urologic malignancies.. Journal of Clinical Oncology, 2020, 38, 400-400.	1.6	0
69	Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. Journal of Clinical Oncology, 2020, 38, 416-416.	1.6	4
70	Clinicopathologic predictors of outcomes in children with stage I germ cell tumors: A pooled post hoc analysis of trials from the Children's Oncology Group.. Journal of Clinical Oncology, 2020, 38, 418-418.	1.6	0
71	Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.. Journal of Clinical Oncology, 2020, 38, 417-417.	1.6	1
72	The Past and Future of Biomarkers in Testicular Germ Cell Tumors. Soci�t� Internationale D'urologie Journal, 2020, 1, 77-84.	0.4	1

#	ARTICLE	IF	CITATIONS
73	First Do No Harm: A Cautious, Risk-adapted Approach to Testicular Cancer Patients. <i>Reviews in Urology</i> , 2020, 22, 85-89.	0.9	0
74	Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 758-764.	1.6	21
75	Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors. <i>Cancer</i> , 2019, 125, 3947-3952.	4.1	14
76	Management of Stage II Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2019, 46, 363-376.	1.8	5
77	Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy. <i>European Urology Oncology</i> , 2019, 2, 691-698.	5.4	18
78	Stereotactic Ablative Radiation Therapy (SABR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 367-375.	0.8	65
79	Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 924-931.	1.6	42
80	MicroRNAs: Turning the Tide in Testicular Cancer. <i>European Urology</i> , 2019, 76, 541-542.	1.9	34
81	PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response. , 2019, 7, 144.		53
82	Stereotactic Ablative Radiotherapy (SAbR) in the Setting of Metastatic Nonseminomatous Germ Cell Tumor of Testis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e768-e771.	1.9	2
83	Lymph node count impacts survival following postchemotherapy retroperitoneal lymphadenectomy for nonseminomatous testicular cancer: a population-based analysis. <i>BJU International</i> , 2019, 124, 792-800.	2.5	12
84	Identification of testicular cancer driver genes by a cross-species comparative oncology approach. <i>Andrology</i> , 2019, 7, 545-554.	3.5	2
85	New insights into germ cell tumor genomics. <i>Andrology</i> , 2019, 7, 507-515.	3.5	23
86	Is Malignant Germ-Cell Tumor Associated With Cowden Syndrome?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e429-e432.	1.9	1
87	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	2.2	9
88	Genetics of testicular germ cell tumors. <i>Current Opinion in Urology</i> , 2019, 29, 344-349.	1.8	10
89	The challenge of matching assays to biology in DNA damage response biomarkers for response to radiotherapy in bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, S514-S516.	1.4	2
90	Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. <i>European Urology Oncology</i> , 2019, 2, 397-404.	5.4	42

#	ARTICLE	IF	CITATIONS
91	Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (18F-Fluciclovine) PET/CT in a Patient With Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e184-e186.	1.9	4
92	Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 57-62.	1.6	24
93	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 967-976.	7.0	164
94	Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. <i>European Urology</i> , 2019, 75, 231-239.	1.9	104
95	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. <i>European Urology Focus</i> , 2019, 5, 365-368.	3.1	20
96	Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 619-619.	1.6	5
97	Assessment of intratumor heterogeneity using imaging texture features in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 663-663.	1.6	0
98	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 651-651.	1.6	0
99	Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 599-599.	1.6	0
100	Pathologic response and surgical outcomes in patients undergoing nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16102-e16102.	1.6	0
101	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16100-e16100.	1.6	0
102	Dynamic contrast-enhanced MRI to predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4580-4580.	1.6	0
103	The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. <i>Urology</i> , 2018, 115, 119-124.	1.0	19
104	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. <i>European Urology Focus</i> , 2018, 4, 995-1001.	3.1	26
105	Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 199, 1440-1445.	0.4	53
106	Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018, 36, 645-653.	2.2	2
107	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. <i>Urology</i> , 2018, 112, 103-111.	1.0	15
108	Reply. <i>Urology</i> , 2018, 112, 111.	1.0	0

#	ARTICLE	IF	CITATIONS
109	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 159.e7-159.e17.	1.6	21
110	Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018, 73, e98-e99.	1.9	2
111	Impact of hospital case volume on testicular cancer outcomes and practice patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 14.e7-14.e15.	1.6	55
112	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e113-e120.	1.9	7
113	Natural history of "second" biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. <i>BJU International</i> , 2018, 121, 365-372.	2.5	12
114	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	3.0	29
115	Editorial comment. <i>Current Opinion in Urology</i> , 2018, 28, 433-434.	1.8	0
116	Update on epidemiologic considerations and treatment trends in testicular cancer. <i>Current Opinion in Urology</i> , 2018, 28, 440-447.	1.8	22
117	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1221-e1235.	1.9	14
118	Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. <i>European Urology Oncology</i> , 2018, 1, 242-251.	5.4	14
119	Metastatic "Burned Out" Seminoma Causing Neurological Paraneoplastic Syndrome "Not Quite Burned Out". <i>Frontiers in Neurology</i> , 2018, 9, 20.	2.4	8
120	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 343.e1-343.e8.	1.6	4
121	Germ Cell Tumors: Updates on Epidemiology, Biology, and Treatment Considerations. <i>Advances in Urology</i> , 2018, 2018, 1-2.	1.3	2
122	Defining the DNA damage repair (DDR) genomic landscape of urothelial carcinoma of the bladder (UCB).. <i>Journal of Clinical Oncology</i> , 2018, 36, 502-502.	1.6	3
123	Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 586-586.	1.6	1
124	Guideline of guidelines: non-muscle-invasive bladder cancer. <i>BJU International</i> , 2017, 119, 371-380.	2.5	195
125	Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence. <i>Journal of Urology</i> , 2017, 198, 546-551.	0.4	8
126	Prospects and progress of immunotherapy for bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-15.	3.1	29

#	ARTICLE	IF	CITATIONS
127	Tissue-based biomarkers in prostate cancer. Expert Review of Precision Medicine and Drug Development, 2017, 2, 249-260.	0.7	20
128	Re: Multi-institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy. European Urology, 2017, 72, 857-858.	1.9	0
129	Testicular germ cell tumor genomics. Current Opinion in Urology, 2017, 27, 41-47.	1.8	18
130	Statin utilization improves oncologic and survival outcomes in patients with dyslipidemia and surgically treated renal cell carcinoma. Minerva Urology and Nephrology, 2017, 69, 501-508.	2.5	4
131	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy, 2017, Volume 10, 1487-1502.	2.0	12
132	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. European Urology, 2017, 72, 952-959.	1.9	263
133	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. Bladder Cancer, 2016, 2, 91-99.	0.4	8
134	Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15Year experience and lessons learned. BMC Urology, 2016, 16, 43.	1.4	24
135	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of Clinical Oncology, 2016, 34, 4000-4007.	1.6	147
136	Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer, 2016, 122, 3715-3723.	4.1	50
137	Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma. Current Urology Reports, 2016, 17, 12.	2.2	30
138	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature Genetics, 2016, 48, 356-358.	21.4	143
139	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. Journal of Urology, 2016, 195, 1684-1689.	0.4	36
140	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. World Journal of Urology, 2016, 34, 105-112.	2.2	7
141	Actionable targets in patients with cisplatin-resistant advanced germ cell tumors.. Journal of Clinical Oncology, 2016, 34, 473-473.	1.6	4
142	Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 268.e1-268.e7.	1.6	24
143	Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 970-977.	1.9	202
144	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2015, 193, 1486-1493.	0.4	38

#	ARTICLE	IF	CITATIONS
145	Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e21-18.e26.	1.6	8
146	Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4510-4510.	1.6	3
147	Impact of renal surgery for cortical neoplasms on lipid metabolism. <i>BJU International</i> , 2014, 114, 837-843.	2.5	7
148	<sc>Ki67</sc> is an independent predictor of oncological outcomes in patients with localized clearâ€cell renal cell carcinoma. <i>BJU International</i> , 2014, 113, 668-673.	2.5	49
149	Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. <i>BJU International</i> , 2014, 113, 70-76.	2.5	38
150	Surgical Management of Renal Cell Carcinoma. <i>Seminars in Interventional Radiology</i> , 2014, 31, 027-032.	0.8	46
151	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tractâ€Is There Evidence for Discordant Biology?. <i>Journal of Urology</i> , 2014, 191, 926-931.	0.4	29
152	Lymphovascular invasion in clear cell renal cell carcinomaâ€Association with disease-free and cancer-specific survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 30.e23-30.e28.	1.6	24
153	Dysregulation of β -Catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 1671-1677.	0.4	22
154	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 28-34.	0.4	35
155	MP77-09 FEASIBILITY OF OBTAINING BIOMARKER PROFILES FROM ENDOSCOPIC BIOPSY SPECIMENS IN UPPER TRACT UROTHELIAL CARCINOMA: PRELIMINARY RESULTS. <i>Journal of Urology</i> , 2014, 191, .	0.4	1
156	Animal Protein and the Risk of Kidney Stones: A Comparative Metabolic Study of Animal Protein Sources. <i>Journal of Urology</i> , 2014, 192, 137-141.	0.4	65
157	Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 981-988.	1.6	39
158	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140.	1.0	18
159	Evaluation of anatomic and morphologic nomogram to predict malignant and high-grade disease in a cohort of patients with small renal masses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 37.e17-37.e23.	1.6	21
160	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e19-54.e26.	1.6	31
161	Does radical nephrectomy increase the risk of erectile dysfunction compared with partial nephrectomy? A cohort analysis. <i>BJU International</i> , 2013, 111, E98-102.	2.5	12
162	Robotic-Assisted Pyeloplasty:Recent Developments in Efficacy, Outcomes, and New Techniques. <i>Current Urology Reports</i> , 2013, 14, 37-40.	2.2	8

#	ARTICLE	IF	CITATIONS
163	Renal Function After Laparoendoscopic Single Site Pyeloplasty. <i>Journal of Urology</i> , 2013, 190, 565-569.	0.4	10
164	Laparoendoscopic Single-site Pyeloplasty: Outcomes of an International Multi-institutional Study of 140 Patients. <i>Urology</i> , 2013, 82, 366-372.	1.0	23
165	Deep Lateral Transurethral Incisions for Recurrent Bladder Neck Contracture: Promising 5-Year Experience Using a Standardized Approach. <i>Urology</i> , 2013, 82, 1430-1435.	1.0	67
166	Prognostic Role of Cell Cycle and Proliferative Biomarkers in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2013, 190, 1662-1667.	0.4	23
167	Preoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus. <i>Journal of Urology</i> , 2013, 190, 452-457.	0.4	25
168	Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma. <i>Urology</i> , 2013, 81, 581-586.	1.0	37
169	Re: Radiotherapy With or Without Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2013, 63, 580-581.	1.9	4
170	Laparoendoscopic Single-site Nephrectomy Compared with Conventional Laparoscopic Nephrectomy: A 5-year, Single-surgeon Experience. <i>European Urology</i> , 2013, 64, 412-418.	1.9	23
171	Favorable Patient Reported Outcomes After Penile Plication for Wide Array of Peyronie Disease Abnormalities. <i>Journal of Urology</i> , 2013, 189, 1019-1024.	0.4	47
172	Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2013, 81, 972-978.	1.0	55
173	Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. <i>European Urology</i> , 2013, 64, 465-471.	1.9	68
174	The use of preoperative targeted molecular therapy to allow nephron sparing for T1b tumors. <i>Current Opinion in Urology</i> , 2013, 23, 411-417.	1.8	4
175	Risk prediction in the management of small renal masses. <i>Current Opinion in Urology</i> , 2012, 22, 347-352.	1.8	10
176	Are we likely to see more of LESS in urological surgery?. <i>Nature Reviews Urology</i> , 2012, 9, 185-186.	3.8	0
177	Initial Results for Combined Orchiectomy and Prosthesis Exchange for Unsalvageable Testicular Torsion in Adolescents: Description of Intravaginal Prosthesis Placement at Orchiectomy. <i>Journal of Urology</i> , 2012, 188, 1424-1428.	0.4	22
178	Surgeon Fatigue: Impact of Case Order on Perioperative Parameters and Patient Outcomes. <i>Journal of Urology</i> , 2012, 188, 1291-1296.	0.4	19
179	Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 62, e27-e29.	1.9	17
180	Comparison of rates and risk factors for development of anaemia and erythropoiesis-stimulating agent utilization after radical or partial nephrectomy. <i>BJU International</i> , 2012, 109, 1019-1025.	2.5	22

#	ARTICLE	IF	CITATIONS
181	Holmium laser endourethrotomy and litholapaxy of an occult prostatic utricle calculus. Canadian Journal of Urology, 2012, 19, 6477-9.	0.0	2
182	Comparison of Rates and Risk Factors for Development of Osteoporosis and Fractures After Radical or Partial Nephrectomy. Urology, 2011, 78, 614-619.	1.0	29
183	Staged Male Urethroplasty Transferring Megalourethra Tissue as Free Graft Dorsal Inlay to Proximal Urethral Atresia in VACTERL Association. Urology, 2011, 78, 1417-1419.	1.0	4
184	Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 27-32.	1.6	78
185	Robot-Assisted Bladder Neck Reconstruction, Bladder Neck Sling, and Appendicovesicostomy in Children: Description of Technique and Initial Results. Journal of Endourology, 2011, 25, 1299-1305.	2.1	56
186	Variation in the incidence of and risk factors for the development of nephrolithiasis after radical or partial nephrectomy. BJU International, 2010, 106, 1200-1204.	2.5	3
187	Residual Fragments After Percutaneous Nephrolithotomy: Cost Comparison of Immediate Second Look Flexible Nephroscopy Versus Expectant Management. Journal of Urology, 2010, 183, 188-193.	0.4	60
188	Complete Transvaginal NOTES Nephrectomy Using Magnetically Anchored Instrumentation. Journal of Endourology, 2009, 23, 367-371.	2.1	69
189	Single-Incision, Umbilical Laparoscopic versus Conventional Laparoscopic Nephrectomy: A Comparison of Perioperative Outcomes and Short-Term Measures of Convalescence. European Urology, 2009, 55, 1198-1206.	1.9	311
190	Impact of body mass index on clinical and cost outcomes after radical cystectomy. BJU International, 2009, 104, 326-330.	2.5	19
191	Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy. BJU International, 2009, 104, 476-481.	2.5	127
192	Perioperative Outcomes in Patients Undergoing Conventional Laparoscopic Versus Laparoendoscopic Single-site Pyeloplasty. Urology, 2009, 74, 1029-1034.	1.0	126
193	Comparison of Tissue Oxygenation Profiles Using 3 Different Methods of Vascular Control During Porcine Partial Nephrectomy. Urology, 2009, 74, 926-931.	1.0	9
194	Ergonomic Considerations of Radical Prostatectomy: Physician Perspective of Open, Laparoscopic, and Robot-Assisted Techniques. Journal of Endourology, 2009, 23, 627-633.	2.1	73
195	Synchronous Bilateral Percutaneous Nephrostolithotomy: Analysis of Clinical Outcomes, Cost and Surgeon Reimbursement. Journal of Urology, 2009, 181, 149-153.	0.4	36
196	Radiation Exposure in the Acute and Short-Term Management of Urolithiasis at 2 Academic Centers. Journal of Urology, 2009, 181, 668-673.	0.4	211
197	Predictors of Cost and Clinical Outcomes of Percutaneous Nephrostolithotomy. Journal of Urology, 2009, 182, 586-590.	0.4	42
198	Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker. Journal of Urology, 2009, 182, 52-58.	0.4	76

#	ARTICLE	IF	CITATIONS
199	How Physician and Patient Perceptions Differ Regarding Medical Management of Stone Disease. Journal of Urology, 2009, 182, 998-1004.	0.4	34
200	Natural History of Residual Fragments Following Percutaneous Nephrostolithotomy. Journal of Urology, 2009, 181, 1163-1168.	0.4	178
201	Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues. Indian Journal of Urology, 2009, 25, 169.	0.6	14
202	Are Urologists Fairly Reimbursed for Complex Procedures: Failure of 22 Modifier?. Urology, 2008, 72, 494-497.	1.0	16
203	Impact of Body Mass Index on Cost and Clinical Outcomes After Percutaneous Nephrostolithotomy. Urology, 2008, 72, 756-760.	1.0	64
204	Does Obesity Impact the Costs of Partial and Radical Nephrectomy?. Journal of Urology, 2008, 179, 1714-1718.	0.4	14
205	Laboratory and Clinical Development of Single Keyhole Umbilical Nephrectomy. Urology, 2007, 70, 1039-1042.	1.0	334